Medtronic (MDT) Stock Price, News & Analysis

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MDT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDT, but not buy additional shares or sell existing shares.
View MDT analyst ratings or view top-rated stocks.

11 equities research analysts have issued 12-month price targets for Medtronic's stock. Their MDT share price targets range from $82.00 to $106.00. On average, they expect the company's share price to reach $93.92 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts price targets for MDT or view top-rated stocks among Wall Street analysts.

Medtronic's stock was trading at $82.38 at the start of the year. Since then, MDT shares have increased by 4.6% and is now trading at $86.18.
View the best growth stocks for 2024 here.

Medtronic saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 11,390,000 shares, an increase of 28.1% from the December 31st total of 8,890,000 shares. Based on an average daily volume of 6,550,000 shares, the short-interest ratio is currently 1.7 days. Approximately 0.9% of the shares of the company are sold short.
View Medtronic's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our MDT earnings forecast.

Medtronic will be holding an earnings conference call on Tuesday, February 20th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Medtronic plc (NYSE:MDT) released its earnings results on Tuesday, November, 21st. The medical technology company reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.07. The medical technology company earned $7.98 billion during the quarter, compared to the consensus estimate of $7.93 billion. Medtronic had a trailing twelve-month return on equity of 13.73% and a net margin of 12.83%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the business posted $1.30 earnings per share.
Read the conference call transcript.

Medtronic declared a quarterly dividend on Thursday, December 7th. Investors of record on Wednesday, December 20th will be given a dividend of $0.69 per share on Friday, January 12th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date is Tuesday, December 19th.
Read our dividend analysis for MDT.

Medtronic (NYSE:MDT) pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.15%. The company has been increasing its dividend for 47 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 89.90%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MDT will have a dividend payout ratio of 50.74% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MDT.

ETFs with the largest weight of Medtronic (NYSE:MDT) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Simplify Health Care ETF (PINK), American Century Focused Large Cap Value ETF (FLV), Leatherback Long/Short Alternative Yield ETF (LBAY), Absolute Select Value ETF (ABEQ), Cambiar Aggressive Value ETF (CAMX), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and Global X Aging Population ETF (AGNG).

Medtronic updated its FY 2024 earnings guidance on Monday, December, 11th. The company provided EPS guidance of 5.130-5.190 for the period, compared to the consensus EPS estimate of 5.120. The company issued revenue guidance of $32.0 billion-$32.0 billion, compared to the consensus revenue estimate of $32.2 billion.

1,925 employees have rated Medtronic Chief Executive Officer Omar S. Ishrak on Glassdoor.com. Omar S. Ishrak has an approval rating of 92% among the company's employees. This puts Omar S. Ishrak in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), Home Depot (HD) and Walmart (WMT).

Medtronic's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (2.17%), Charles Schwab Investment Management Inc. (0.83%), First Eagle Investment Management LLC (0.71%), Dimensional Fund Advisors LP (0.49%), Raymond James & Associates (0.45%) and Fisher Asset Management LLC (0.35%). Insiders that own company stock include Bradley E Lerman, Brett A Wall, Brett A Wall, Carol A Surface, Geoffrey Martha, Gregory L Smith, Hoedt Rob Ten, John R Liddicoat, Karen L Parkhill, Karen L Parkhill, Michael Marinaro, Richard H Anderson, Robert John White and Sean Salmon.
View institutional ownership trends.

Shares of MDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.